PDS Biotechnology (NASDAQ:PDSB) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immunotherapies for cancer and infectious diseases. Headquartered in Hillsborough, New Jersey, the company leverages its proprietary DPX® platform, a lipid‐based delivery system designed to elicit robust and durable T-cell responses against specific disease targets. By encapsulating peptide antigens in a depot formulation, PDS Biotechnology aims to overcome traditional vaccine limitations and enhance antigen presentation to the immune system.
The company’s lead candidate, PDS0101, is an HPV16‐targeted immunotherapy in clinical trials for the treatment of HPV‐driven malignancies such as head and neck and cervical cancers. In addition to monotherapy studies, PDS0101 is being evaluated in combination with immune checkpoint inhibitors to explore synergistic effects and improve patient outcomes. Beyond oncology, PDS Biotechnology is advancing a tuberculosis vaccine program and other infectious disease candidates, using the same DPX® platform to promote long‐lasting cellular immunity.
Founded in the mid-2000s, PDS Biotechnology has built a development pipeline supported by preclinical research and early‐stage clinical trials conducted in North America and Europe. The company went public in 2020, trading on the NASDAQ under the symbol PDSB, to raise capital for its clinical programs and expand manufacturing capabilities. PDS Biotechnology collaborates with academic centers and industry partners to advance its proprietary technology and accelerate the translation of novel immunotherapies into the clinic.
Guided by a leadership team with extensive experience in biotechnology and immuno‐oncology, PDS Biotechnology continues to refine its DPX® platform and grow its pipeline. The management team draws on decades of scientific, clinical and regulatory expertise to navigate complex development pathways and deliver potential new treatment options for patients with limited therapeutic alternatives.
